Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: "Michael Spedding" Clear advanced filters
  • Humans evolved to run. This helps to explain our athletic capacity and our susceptibility to modern diseases, argue Timothy Noakes and Michael Spedding.

    • Timothy Noakes
    • Michael Spedding
    Comments & Opinion
    Nature
    Volume: 487, P: 295-296
  • Despite the clear need for better therapies for psychiatric disorders such as depression and schizophrenia, novel drugs — particularly those that could revolutionize treatment — have been rare in recent years. Following a symposium in which the underlying reasons for this problem were discussed, a group of experts from across the field of neuroscience highlight key advances in our understanding of psychiatric disorders, and propose steps that can be taken to improve the effectiveness of drug discovery in this field.

    • Yves Agid
    • György Buzsáki
    • Daniel Weinberger
    Reviews
    Nature Reviews Drug Discovery
    Volume: 6, P: 189-201
  • Studies of psychiatric disorders have traditionally focused on emotional symptoms, such as depression, anxiety and hallucinations, but poorly controlled cognitive deficits are also prominent and severely compromise quality of life. This article critically discusses our understanding of the nature and causes of cognitive impairment in psychiatric disorders, and reviews the opportunities and challenges in improving cognition in patients, including the development of more effective translational research approaches.

    • Mark J. Millan
    • Yves Agid
    • Larry J. Young
    Reviews
    Nature Reviews Drug Discovery
    Volume: 11, P: 141-168
  • Advances in the understanding of the genetic and environmental causes of schizophrenia, and their relationship to aberrant patterns of neurodevelopment, have led to growing interest in the possibility that 'disease-modifying' strategies could alter the course to — and of — this debilitating disorder, rather than just alleviating its symptoms. This article provides a broad-based consideration of the challenges and opportunities inherent in such efforts.

    • Mark J. Millan
    • Annie Andrieux
    • Daniel Weinberger
    Reviews
    Nature Reviews Drug Discovery
    Volume: 15, P: 485-515